Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Analysis of Genasense trial confirms major efficacy variables in patients with melanoma
February 27th, 2006
Genta Incorporated (GNTA) announced the presentation of analyses that confirmed the major efficacy variables from the company's randomized phase III trial of Genasense (oblimersen) plus chemotherapy in patients with advanced metastatic melanoma. The data were presented in Paris, France at the 17th International Congress on Anticancer Treatment by Alexander Eggermont from the Daniel den Hoed Cancer Center, Erasmus University, Rotterdam, The Netherlands. Eggermont is the current president of the European Organization on Research and Treatment of Cancer (EORTC). Recent studies conducted by the EORTC and other groups have shown that elevation of serum...
Source: Pharma Business Week (2006-02-27)
|
